Idéal Investisseur
Français English
CAC 40 :
8 157,82 pts
-0.84%


Last updated : 24/04/2026 - 17h35
🏠 Home   ➤    Stock news

DBV Technologies: +229% Yearly Gain as the Stock Continues Its Rally

DBV Technologies saw a rise of 2.21% this Wednesday, reaching 3.705 euros, in a generally bullish Parisian market. The biotech company specializing in food allergies continues its positive momentum, having increased by over 10% in the past seven days. Over the year, the performance has reached 229%, showcasing a spectacular stock market journey.


DBV Technologies: +229% Yearly Gain as the Stock Continues Its Rally

Technical Analysis and Market Position

DBV Technologies' stock is currently trading above its 20-day moving average (3.59 euros) and significantly above its 200-day moving average (2.59 euros), confirming the strong upward trend initiated in recent months. However, the price is slightly below its 50-day moving average at 3.71 euros, a technical threshold whose sustainable crossing could signal a bullish consolidation. The Relative Strength Index (RSI), which measures the speed and magnitude of recent price changes, stabilizes at 52: a neutral level, away from overbought or oversold zones, allowing room for movement in both directions. Key levels include a support at 3.37 euros, while immediate resistance at 4.04 euros nearly coincides with the upper Bollinger band (4.00 euros). Breaking through this zone could pave the way for a new appreciation phase.

Market Context and Comparative Performance

Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
Before 9 AM every morning Euronext data AI-powered analysis

DBV Technologies' progress occurs amidst turbulent market conditions. The CAC 40 is up 2.12% during the session, at 7,982.50 points, following a highly stressful end to the previous week: the VIX, a volatility index, was at 31.05 at the close of Friday, March 27, up more than 13% in one session, a level considered extremely tense. The negative beta of the stock (-0.10) indicates that DBV Technologies largely moves independently from major indices, which may explain why the stock is not directly affected by current geopolitical tensions. Among comparable sector stocks, UCB is up 3.17% while Sanofi advances 0.52% in the session. The one-month volatility of DBV Technologies stands at 22.40, a relatively contained level considering its history and the magnitude of recent movements. Over three months, the stock has gained 9.62%, confirming the consistency of its upward trajectory.



Sector Santé · Biotechnologies · Pharmacie Biotechnologie


Assurance vie

Context

Period
  • Period: 3T 2025
Guidance from the release
  • Perte nette trimestrielle de (33,2) millions de dollars ; trésorerie de 69,8 millions de dollars au 30/09/2025 suite à un financement partiel (125,5 M$ reçu) et un programme ATM ; dépenses opérationnelles élevées principalement en R&D (83,8 M$ sur 9 mois). Trésorerie estimée suffisante jusqu'au T3 2026 mais incertitude significative persiste.
Risks mentioned
  • Incertitude significative sur la continuité d'exploitation (trésorerie insuffisante pour couvrir 12 prochains mois)
  • Dépendance aux financements externes (PIPE, ATM et autres levées de fonds)
  • Accès futur aux capitaux soumis aux conditions du marché et à l'intérêt des investisseurs
  • Dépendance aux résultats de l'étude de phase 3 VITESSE pour accélération d'exercices de BSA et financements supplémentaires
Opportunities identified
  • Financement pouvant atteindre 306,9 millions de dollars via PIPE
  • Programme ATM pouvant générer jusqu'à 150,0 millions de dollars
  • Potentiel réglementaire et commercial du patch Viaskin® Peanut (BLA et lancement aux États-Unis si approuvé)
  • Possibilité d'exercices supplémentaires de bons de souscription si certains critères sont atteints

The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.

Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.

Advertisement
Every morning
Technical market signals,
before the opening bell.
CAC 40 · SBF 120 · Signals · Analysts
🤖
Today's edition — pre-market
CAC 40
7 702
-0,87%
SBF 120
5 827
-0,87%
📈 Bullish signals
+5,2%
+1,8%
+0,9%
📉 Bearish signals
-14%
-5,7%
🔄 Analyst opinions
▲ 35 €
▼ 80 €
Sign up to see everything →
Before 9 AM every morning
Euronext data
AI-powered analysis





BOURSE · Chaque matin
La synthèse bourse,
avant l'ouverture.
Notre moteur analyse chaque nuit le CAC 40 et le SBF 120. Ce qui mérite attention remonte directement dans votre boîte mail. Gratuit.
Avant 9h00 1000+ inscrits 100% gratuit